Managing type 2 diabetes often means keeping several health risks under control at the same time. Alongside blood sugar, many patients must also monitor their blood pressure to help protect vital organs, including the kidneys.
Now, researchers are examining whether a commonly prescribed blood pressure medication could have unintended consequences for some diabetes patients.
According to research presented at the European Renal Association Congress and reported by Medical News Today, a class of drugs known as dihydropyridine calcium-channel blockers (DCCBs) may be linked to faster progression of kidney disease in people with type 2 diabetes.
New findings
The research team reviewed health data from more than 31,000 adults living with type 2 diabetes. All participants were already receiving treatments designed to help manage blood pressure and protect kidney function.
Also read: Expert says most people miss the real signs of a lie
After comparing different treatment approaches, researchers found that patients using DCCBs appeared more likely to experience serious kidney-related complications than those receiving alternative blood pressure medications.
Not the final word
While the findings have attracted attention, experts caution against drawing firm conclusions too quickly. Because the study was observational, it cannot prove that the medication directly caused poorer kidney outcomes.
Researchers say additional studies will be needed to confirm the results and determine whether treatment recommendations should eventually change.
For now, specialists advise patients not to alter their medication without speaking to their healthcare provider. The study instead highlights the need for continued research into how best to balance blood pressure control with long-term kidney protection in people living with type 2 diabetes.
Also read: These foods may help you fall asleep faster
Sources: Medical News Today
Also read: New obesity drug reduced sleep apnea by 60 percent in trials